<< Bob, I think that most readers on the board know where the vast majority of my info originates. >>
It should be obvious, to everyone, that you have a significant depth of understanding of Ligand's science, and that you do a considerable amount of research into related events. Since LGND doesn't live in a vacuum (for instance, there's over 360 new cancer drugs under development), I appreciate ALL of the biotech information that you provide to this thread.
Many investors spend considerable time trying to research their stocks. You have provided this thread with a wealth of information. This doesn't mean that LGND is a good or bad investment. Let the reader draw his/her own opinion.
I just dislike personal attacks.
As far as LGND: Henry, now that LGND has gotten the "fast track" with Panretin Gel, we will see the value of Ligand's earlier delay to supply extra information on the NDA.
ONTAK also had "fast track" designation, but the NDA submission fell short, IMHO, as evidenced by the FDA requesting more info.
If LGND did a good job with it's Panretin Gel NDA, we could see how well the FDA's "fast track" process works, when all the pieces, hopefully, are in place. The question is: Is Ligand's NDA submission strong enough for a quick approval!
Good luck, Bob |
